Controversies on the management of clinical situations with low therapeutic effectiveness in oncology
- 20 July 2010
- journal article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 12 (7) , 493-498
Abstract
Clinical scenarios associated with low therapeutic effectiveness (LTE) are especially complex and highly relevant in oncology. The objective was to test a methodological framework for creating consensual clinical recommendations for routine practice. The study was in three phases from Mars 2006 to January 2008: 1) Definition of LTE situations; 2) Preparation by 10 experts of a panel of LTE situations in cancers of breast, lung, head and neck, colon and rectum and brain; and 3) Development of a consensus on each situation and its optimal treatment by gathering agreement and disagreements (two-round Delphi method) from 68 practicing oncologists in Andalusian Community. Three major and three minor criteria were established for an LTE situation, defined when at least one major or two minor criteria were met. The expert group proposed 48 possible LTE clinical scenarios for breast (n = 7), lung (10), brain (11), head and neck (11) and colorectal cancers (9). Sixty-eight oncologists agreed to participate in the study; the response rate was 79% (from 34 medical and 17 radiation oncologists) In the first round (definition), maximum agreement was obtained with the LTE definition of 10 of the 48 scenarios; in the second round (treatment options), maximum agreement was obtained on the treatment of 3 of these 10 scenarios. Oncologists reached low levels of agreement on the definition of an LTE situation and on its treatment recommendations. This study proposes an approach to the improvement of cancer management in situations of high uncertainty.Keywords
This publication has 21 references indexed in Scilit:
- Emerging drugs for non-small-cell lung cancerExpert Opinion on Emerging Drugs, 2007
- The rising burden of cancer in the developing worldAnnals of Oncology, 2006
- Target Practice: Figuring Out Which, When, and Why to Use Systemic Therapies for Metastatic Colon CancerCancer Investigation, 2006
- Method of Presenting Oncology Treatment Outcomes Influences Patient Treatment Decision-Making in Metastatic Colorectal CancerAnnals of Surgical Oncology, 2006
- Analysis of clinical decision-making in multi-disciplinary cancer teamsAnnals of Oncology, 2005
- Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly StudyJournal of Clinical Oncology, 2005
- ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC)Annals of Oncology, 2005
- Developing a System to Assess the Quality of Cancer Care: ASCO's National Initiative on Cancer Care QualityJournal of Clinical Oncology, 2004
- Levels of absolute survival benefit for systemic therapies of advanced cancerEuropean Journal of Cancer, 2003
- Understanding the Treatment Preferences of Seriously Ill PatientsNew England Journal of Medicine, 2002